Our Patents:

Luciano et al. patent 6,063,028 et patent 6,317,731

ABL is pleased to announce the acquisition and ownership of 2 US patents (Luciano – 6,063,028 and Luciano – 6,317,731) having as main inventor Dr Joanne Luciano.

Schinazi et al. patent 5,631,128, patent 5,650,268, patent 5,856,086 et patent 6,503,705

Advanced Biological Laboratories (ABL) SA, a Luxembourg-based company developing personalized medicine IT systems in the fields of infectious disease, is pleased to announce an exclusive and global license agreement with Emory University (Atlanta, Georgia) for the commercialization of a novel HIV-1 reverse transcriptase codon deletion and in all fields of use, including the management of HIV infections. Financial terms were not disclosed.ABL with this new licensing agreement continue strengthening its patent estate which is covering computational systems for personalized medicine in the field of chronic diseases such as, but not limited to, HIV/AIDS, liver diseases and affective disorders.
International Publication

Our Patent licensees :

Luciano et al:

Other agreement

News, Press releases (Patents)

HepatiC® trademark registration

ABL is pleased to announce that its mark HepatiC® has now achieved registration with the United States Patent and Trademark Office on the Supplemental Register with N° 4,661,252.
The HepatiC® software is a patient register to monitor HCV-infected patients in particular for ones using Direct Antiviral Agents which has been developed together with the Spanish Association for Liver Diseases.

Exclusive licensing agreement with CRP-Santé for “COMET” software

ABL entered into an exclusive worldwide licensing agreement with CRP-Santé for its COMET software designed for high performance DNA sequencing analysis and classification.See full Press Release.

ABL acquires Evivar Medical Assets and further enhances its IT Solutions and Personalized Healthcare Platform for Hepatitis B, Hepatitis C and HIV Infections

Please see the full Press Release at Businesswire

South African Patent

ABL is pleased to report the South African Patent Office has been issued patent N° 2009/07533 and has been granted for 20 years from the filing date, April 10, 2008. This patent is related to the Emory Patent Internal Application WO/2008/124192.

Link to the issued patent

ABL Enters into an International Distribution and Licence Agreement for the virco®TYPE HIV Resistance Interpretation System Through ABL’s TherapyEdge®-ViroScore® Platform

LUXEMBOURG–(BUSINESS WIRE)–Advanced Biological Laboratories (ABL) is pleased to announce its recent signature of a non-exclusive international distribution agreement (excluding United States, Australia, Canada and United Kingdom) of virco®TYPE HIV-1, Belgium-based Virco BVBA’s HIV resistance interpretation system.

ABL will offer virco®TYPE HIV-1 through its electronic medical record and decision support system TherapyEdge® HIV. virco®TYPE HIV-1 results (raw data and report) will be available together with full patient’s details and will support the healthcare providers’ virological and clinical decisions taking care of HIV-infected patients experiencing virological failure and HIV drug resistance.

See the press release

ABL Licensed CRP-Santé COMET Subtyping Tool

Advanced Biological Laboratories (ABL) S.A. and Luxembourg Centre de Recherche Public pour la Santé CRP-Santé announced a non-exclusive licensing and distribution agreement to implement CRP-Santé COMET subtyping tool on ABL TherapyEdge® Platform.

See the brochure

Centro de Genomas®

ABL is pleased to announce that Centro de Genomas® is as of Oct 15th 2009 the TherapyEdge® local agent in Brazil and will present the TherapyEdge® and ViroScore® products at the “XVI Congresso Brasileiro de Infectologia” which will be held from October the 18th to October the 21st at Maceió, BRAZIL.
See the brochure

If you are interested in our patents, please contact us at

Comments are closed.